Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(9):715-716; doi:10.1093/jnci/djh127
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Lu, C.
Right arrow Articles by Brown, P. H.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Lu, C.
Right arrow Articles by Brown, P. H.
Related Collections
Right arrowCorrespondence about this Article
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

CORRESPONDENCE

RESPONSE: Re: Effect of Epidermal Growth Factor Receptor Inhibitor on Development of Estrogen Receptor-Negative Mammary Tumors

Chunhua Lu, Syed K. Mohsin, Susan Hilsenbeck, Alan Wakeling, Powel H. Brown

Affiliations of authors: Departments of Medicine and Molecular and Cellular Biology, Breast Center, Baylor College of Medicine, Houston, TX (CL, SM, SH, PHB); AstraZeneca, Macclesfield, UK (AW).

Correspondence to: Powel Brown, MD, PhD, Baylor College of Medicine, One Baylor Plaza, MS: 600, Houston, TX 77030 (e-mail: pbrown@breastcenter.tmc.edu)

The first 10% of the full text of this article appears below.

In their correspondence, Campiglio et al. comment that epidermal growth factor receptor (EGFR) blockade induced by the tyrosine kinase inhibitor ZD1839 (i.e., gefitinib) may offer new opportunities to fight breast cancer. We certainly agree and appreciate their comments pertaining to our recently reported results (1). They also raised very reasonable questions about the mechanism by which this agent suppresses mammary tumor development. We would like to respond to these important questions.

First, the authors asked whether the data from our recent experiments showing that . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Correspondence about this Article

Re: Effect of Epidermal Growth Factor Receptor Inhibitor on Development of Estrogen Receptor–Negative Mammary Tumors
Manuela Campiglio, Nicola Normanno, and Sylvie Ménard
J Natl Cancer Inst 2004 96: 715. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
T. E. Strecker, Q. Shen, Y. Zhang, J. L. Hill, Y. Li, C. Wang, H.-T. Kim, T. M. Gilmer, K. R. Sexton, S. G. Hilsenbeck, et al.
Effect of Lapatinib on the Development of Estrogen Receptor-Negative Mammary Tumors in Mice
J Natl Cancer Inst, January 21, 2009; 101(2): 107 - 113.
[Abstract] [Full Text] [PDF]